- Home
- JMM vs ALLK Comparison
JMM vs ALLK Comparison
Compare JMM & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMM
- ALLK
- Stock Information
- Founded
- JMM 1988
- ALLK 2012
- Country
- JMM United States
- ALLK United States
- Employees
- JMM N/A
- ALLK N/A
- Industry
- JMM Trusts Except Educational Religious and Charitable
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- JMM Finance
- ALLK Health Care
- Exchange
- JMM Nasdaq
- ALLK Nasdaq
- Market Cap
- JMM 57.1M
- ALLK 58.0M
- IPO Year
- JMM N/A
- ALLK 2018
- Fundamental
- Price
- JMM $6.01
- ALLK $1.16
- Analyst Decision
- JMM
- ALLK Hold
- Analyst Count
- JMM 0
- ALLK 5
- Target Price
- JMM N/A
- ALLK $1.67
- AVG Volume (30 Days)
- JMM 16.1K
- ALLK 1.3M
- Earning Date
- JMM 01-01-0001
- ALLK 11-06-2024
- Dividend Yield
- JMM 5.44%
- ALLK N/A
- EPS Growth
- JMM N/A
- ALLK N/A
- EPS
- JMM N/A
- ALLK N/A
- Revenue
- JMM N/A
- ALLK N/A
- Revenue This Year
- JMM N/A
- ALLK N/A
- Revenue Next Year
- JMM N/A
- ALLK N/A
- P/E Ratio
- JMM N/A
- ALLK N/A
- Revenue Growth
- JMM N/A
- ALLK N/A
- 52 Week Low
- JMM $5.29
- ALLK $0.54
- 52 Week High
- JMM $6.10
- ALLK $3.41
- Technical
- Relative Strength Index (RSI)
- JMM 40.87
- ALLK 51.18
- Support Level
- JMM $5.95
- ALLK $1.29
- Resistance Level
- JMM $6.23
- ALLK $1.56
- Average True Range (ATR)
- JMM 0.07
- ALLK 0.14
- MACD
- JMM 0.01
- ALLK -0.03
- Stochastic Oscillator
- JMM 21.43
- ALLK 14.89
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund seeks to invest in debt securities, including, but not limited to, U.S. agency and privately issued mortgage-backed securities, corporate debt securities, and asset-backed securities.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.